癲癇與糖尿病的相關性研究進展_Journal of Epilepsy

Authors：

 陳成

揚州大學醫學院（揚州 225000）;

Corresponding?author：

陳成, Email: bainiandeshu@163.com

Keywords：

癲癇; 糖尿病; 共患病; 相關性

DOI：

10.7507/2096-0247.20210056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

隨著糖尿病（Diabetes mellitus，DM）和癲癇患病率的不斷增加，兩者共病的現象已不少見，且大量流行病學調查顯示，DM 和癲癇存在相關性。目前，國內外對于癲癇共病 DM 的認識仍不充分。本文就流行病學、基因層面、DM 促進癲癇發病的機制以及兩者分別與相關療法或藥物之間的關系等方面對癲癇和 DM 的相關性展開綜述，并總結文獻對癲癇共病 DM 的治療提出建議，為早期識別和防治提供依據。

Citation： 陳成. 癲癇與糖尿病的相關性研究進展. Journal of Epilepsy, 2021, 7(4): 343-349. doi: 10.7507/2096-0247.20210056 Copy

1.	Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020, 369: m997.
2.	Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
3.	Keezer MR, Novy J, Sander JW. Type 1 diabetes mellitus in people with Pharmacoresistant epilepsy: Prevalence and clinical characteristics. Epilepsy Res, 2015, 115: 55-57.
4.	TiamkaoS, Pratipanawatr T, Tiamkao S, et al. Seizures in nonketotic hyperglycaemia perglycaemia. Seizure, 2003, 12(6): 409-410.
5.	Schober E, Otto K P, Dost A, et al. Association of epilepsy and type 1 diabetes mellitus in children and adolescents: Is there an increased risk for diabetic ketoacidosis? J Pediatr, 2012, 160(4): 662-666.
6.	Dafoulas GE, Toulis KA, Mccorry D, et al. Type 1 diabetes mellitus and risk of incidentpilepsy: apopulation-based, open-cohort study. Diabetologia, 2016, 60(2): 258-261.
7.	Chou IC, Wang CH, Lin WD, et al. Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study. Diabetologia, 2016, 59(6): 1196-1203.
8.	Mastrangelo M, Tromba V, Silvestri F, et al. Epilepsy in children withtype 1 diabetes mellitus: Pathophysiological basis and clinical hallmarks. Eur J Paediatr Neurol, 2019, 23(2): 240-247.
9.	Yan D, Zhao E, Zhang H, et al. Associationbetween Type 1 diabetes mellitus and risk of epilepsy: A meta-analysis of observational studies. DrugDiscovTher, 2017, 11(3): 146-151.
10.	Marcovecchio ML, Petrosino MI, Chiarelli F. Diabetes and epilepsy in children andadolescents. Curr Diab Rep, 2015, 15(4): 21.
11.	Lu CL, Chang YH, Sun Y, et al. A population-based study of epilepsy incidence in association with type 2 diabetes and severe hypoglycaemia. Diabetes Research and Clinical Practice, 2018, 140: 97-106.
12.	Mccorry D, Nicolson A, Smith D, et al. An association between type 1 diabetes and idiopathic generalized epilepsy. AnnNeurol, 2006, 59(1): 204-206.
13.	Hamed SA. Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions. Epilepsy Res, 2007, 75(1): 1-9.
14.	Doneray H, Houghton J, Tekgunduz KS, et al. Permanent neonatal diabetes mellitus caused by anovel mutation in the KCNJ11 gene. J Pediatr Endocrinol Metab, 2014, 27(3-4): 367-371.
15.	Masia R, Koster JC, Tumini S, et al. An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal Diabetes. Diabetes, 2007, 56(2): 328-336.
16.	Poulton C, Schot R, Kia S, et al. Microcephaly with Simplified Gyration, Epilepsy, and Infantile Diabetes Linked to Inappropriate Apoptosis of NeuralProgenitors. AmJHumGenet, 2011, 89(2): 265-276.
17.	Verrotti A, Scaparrotta A, Olivieri C, et al. Seizures and type 1 diabetes mellitus: current state of knowledge. Eur J Endocrinol, 2012, 167(6): 749-758.
18.	Antony S, Kumar TP, Kuruvilla KP, et al. Decreased GABA receptor binding in the cerebral cortex of insulin induced Hypogly cemic and Streptozocin induced diabetes rats. Neurochem Res, 2010, 35(10): 1516-21.
19.	Szeto V, Chen NH, Sun HS, et al. The role of KATP channels in cerebra ischemic stroke and diabetes. ActaPharmacolSin, 2018, 39(5): 683-694.
20.	Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med, 2011, 49(3): 435-41.
21.	Gorgone G, Caccamo D, Pisani L R, et al. Hyperhomocysteinemia in patients with epilepsy: Does it play a role in the pathogenesis of brain atrophy? A preliminary report. Epilepsia, 2009, 50(1): 33-36.
22.	Quan Y, Barszczyk A, Feng ZP, et al. Current understanding of KATP channels in neonatal diseases: focus on insulin secretion disorders. Acta Pharmacol Sin, 2011, 32(6): 765-780.
23.	Velísek L, Velísková J, Chudomel O, et al. Metabolic environment in substantia nigra reticulata is critical for the expression and controlof hypoglycemia-induced seizure. J Neurosci, 2008, 28(38): 9349-9362.
24.	Lv RJ, He JS, Fu Y H, et al. ASIC1a polymorphism is associated with temporal lobe epilepsy. Epilepsy Res, 2011, 96(1-2): 74-80.
25.	魏東. 酸敏感離子通道 1a 的通道開放、藥物調控及其在癲癇發生中的作用. 西安: 第四軍醫大學, 博士學位論文, 2015.
26.	Wang YC, Li WZ, Wu Y, et al. Acid-sensing ion channel 1a contributes to the effect of extracellular acidosis on NLRP1 inflammasome activation in cortical neurons. J Neuroinflammation, 2015, 12: 246.
27.	Ziemann AE, Schizler MK, Albert GW, et al. Seizure termination by acidosis depends on ASIC1a. Nat Neurosci, 2008, 11(7): 816-822.
28.	Cho JH, Askwith CC. Presynaptic ralease probability is increased inHippocampal neurons from ASIC1 knockout mice. J Neurophysiol, 2008, 99(2): 426-41.
29.	Ievglevsky O, Isae D, Netsy O, et al. Acid-sensing ion channels regulate spontaneous inhibitory activity in the hippocampus: possibleImplications for epilepsy. Philos Trans R Soc Lond B Biol Sci, 2016, 371(1700): 20150431.
30.	郭為. 酸敏感離子通道 1a 在大腦皮質發育不良病理發生中的作用研究. 重慶: 第三軍醫大學, 博士學位論文, 2014.
31.	陳勇, 葛金芳, 陳飛虎. 酸敏感離子通道 1a 在自身免疫性疾病發病機制中的研究進展. 中國藥理學通報, 2018, 34(1): 12-15.
32.	張海濤. 海馬區神經元葡萄糖低代謝在癲癇發生中的作用及機制研究. 西安: 第四軍醫大學, 博士學位論文, 2017.
33.	Moloney TC, Idris I, Waters P, et al. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study. J Neurol Neurosurg Psychiatry, 2016, 87(6): 676-677.
34.	Liimatainen S, Honnorat J, Pittock SJ, et al. GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies. Orphanet J Rare Dis, 2018, 13(1): 55.
35.	kash SF, Johnson RS, Tecott LH, et al. Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Nat1 Acad Sci USA, 1997: 94.
36.	Mahmoud AA, Abdelmagid T, Alghofely M, et al. Epilepsy in patients with insulin-dependent diabetes and relation to glutamic acid decarboxylase 65. Neurosciences, 2020, 25(3): 200-204.
37.	Mitoma H, Song SY, Ishida K, et al. Presyhaptic impair ment of cerebellar inhibitory synapses by an auto antibody toglutamate decar boxylase. J Neurol Sci, 2000, 175: 40-44.
38.	Tao H, Zhou X, Zhao B, et al. Conflicting effects of methylglyoxal and potential significance of miRNAs for seizure treatment. Front Mol Neurosci, 2018, 11: 70.
39.	Byun K, Bayarsaikhan E, Kim D, et al. Activated microglial cells synthesize and secrete AGE-albumin. Ana Cell Biol, 2012, 45(1): 47-52.
40.	Alyu F, Dikmen M. Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms. Acta Neuropsychiatr, 2017, 29(1): 1-16.
41.	劉卉, 姜振鋒, 姚麗芬. 晚期糖基化終末產物受體與癲癇炎癥機制相關性的研究. 腦與神經疾病雜志, 2019, 27(9): 592-595.
42.	陳勝利, 曹立榮, 紀盛章. 非酮癥性高血糖腦部影像學表現. 臨床放射學雜志, 2009, 28(2): 163-166.
43.	Jin R, Jin ZG, Cai H. Influence of electroacupuncture plus jasminoidia intervention on expression of OX-42 and nuclear factor-kappa B in hippocampus and amygdale in cerebral ischemia plus diabetes rats. Acupuncture research, 2014, 39(4): 305-312.
44.	Shlobin NA, Sander JW. Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review. Epilepsy Behav, 2020, 106: 107043.
45.	Miklossy J, McGeer PL. Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. Aging (Albany NY), 2016, 8(4): 575-588.
46.	Vezzani A, Fujinami RS, White HS, et al. Infections, inflammation and epilepsy. Acta Neuropathol, 2016, 131(2): 211-234.
47.	楊華俊, 郭安臣, 王群. 癲癇的發病機制研究進展. 科技導報, 2017, 35(4): 54-59.
48.	Jordan AJ, Manor B, Novak V. Slow gaitspeed-an indicator of lowercere bralvaso reactivity in type 2 diabetes mellitus. Frontiersin Aging Neuroscience, 2014, 6: 135.
49.	Poittevin M, Bonnin P, Pimpie C, et al. Diabetic microangiopathy: Impact of impaired cerebral vasoreactivity and delayed angiogenesisafter permanent middle cerebral artery occlusion on stroke damage andcerebral repair in mice. Diabetes, 2015, 64(3): 999-1010.
50.	殷盛明, 劉純青, 高溪, 等. 大鼠腦缺血對癲癇敏感性和腦內膠質原纖維酸性蛋白免疫反應的影響. 基礎醫學與臨床, 2003, (1): 53-58.
51.	Xia L, Lei Z, Shi Z, et al. Enhanced autophagy signaling in diabeticrats with ischemia-induced seizures. Brain Res. 2016, 1643: 18-26.
52.	PrasadS, SajjaRK, NaikP, et al. Diabetes mellitus and blood-brain Barrier dysfunction: an overview. J Pharmacovigil, 2014, 2(2): 125.
53.	Vavilala MS, Richards TL, Roberts JS, et al. Change in blood-brain barrier permeability during pediatric diabetic ketoacidosis treatment. Pediatric Critical Care Medicine, 2010, 11(3): 332-338.
54.	Fouyas IP, Kelly PA, Ritchie IM, et al. Cerebrovascular responses to pathophysiological insult in diabetic cats. J Clin Neurosci, 2003, 10: 88-91.
55.	Dadas A, Janigro D. Breakdown of blood brain barrier asa mechanism of post-traumatic epilepsy. Neurobiol Dis, 2019, 23: 20.
56.	Abdullahi W, Brzica H, Hirsch NA, et al. Functional expression of organic anion transporting polypeptide 1a4Is regulated by transforming growth factor-β/activin rector-like kinase 1 signaling at the blood-brain barrier. MolPharmacol, 2018, 94(6): 1321.
57.	Hawkins RA, O'kane RL, Simpson IA, et al. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr, 2006, 136(1): 218-226.
58.	耿喜林, 徐明麗, 尹潔, 等. 糖尿病早期腦損傷與線粒體功能障礙. 中國病理生理雜志, 2012, 28(9): 1571-1576.
59.	姜東朗, 馮洪波, 邱湘哲, 等. ¹⁸F-FDGPET/CT 評價糖尿病前期患者腦葡萄糖代謝的改變. 中國醫學影像技術, 2016, 32(8): 1184-1188.
60.	Zilberter Y, Zilberter M. The vicious circle of hypometabolism inNeurodegenerative diseases: Ways and mechanisms of matabolic correction. JNeurosciRes, 2017, 95(11): 2217-2235.
61.	Shima T, Jesmin S, Matsui T, et al. Differential effects of type 2 diabetes on brain glycometabolism in rats: focus on glycogen and monacarboxylate transporter 2. J Physiol Sci, 2018, 68(1): 69-75.
62.	DiNuzzo M, Mangia S, Maraviglia B, et al. Does abnormal glycogen structure contribute to increased susceptibility to seizures in epilepsy. Metab Brain Dis, 2015, 30(1): 307-316.
63.	Tricò D, Herzog RI. Metabolic brain adaptations to recurrent hypoglycaemia may explain the link between type 1 diabetes mellitus andepilepsy and point towards future study and treatment options. Diabetologia, 2017, 60(5): 938-939.
64.	王慧萌, 趙志剛. 血糖水平對糖尿病缺血性腦損傷影響研究進展. 中華實用診斷與治療雜志, 2016, 30(2): 114-116.
65.	朱責梅, 楊絲絲, 伍迪, 等. 胰島素抵抗與糖尿病腦病. 生理科學進展, 2016, 47(5): 395-400.
66.	周佳秀, 田紹文, 曠昕. 能量代謝在癲癇疾病中的研究進展. 新醫學, 2019, 50(12): 881-885.
67.	Stauss HM, Stangl H, Clark KC, et al. Cervical vagal nerve stimulation impairs glucose tolerance and suppresses insulin release in conscious rats. Physiol Rep, 2018, 6(24): e13953.
68.	Meyers EE, Kronemberger A, Lira V, et al. Contrasting effects of afferent and efferent vagal nerve stimulation on insulin secretion and Blood glucose regulation. Physiol Rep, 2016, 4(4): e12718.
69.	江波, 鄒大進, 馬向華, 等. 生酮飲食干預2型糖尿病中國專家共識(2019年版). 實用臨床醫藥雜志, 2019, 23(3): 1-6.
70.	Bolla AM, Caretto A, Laurenzi A, et al. Low-carb and ketogenic diets in type 1 and type 2 diabetes. Nutrients, 2019, 11(5): 962.
71.	Genc BO, Dogan EA, Dogan U, et al. Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic Epilepsy receiving topiramate treatment. J Clin Neurosci, 2010, 17(10): 1256-1259.
72.	Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: An update. Am Fam Physician, 2016, 94(3): 227-234.
73.	Lee JTC, Shanina I, Chu YN, et al. Carbamazepine, a beta-cell protecting Drug, reduces type 1 diabetes incidence in NOD mice. Sci Rep, 2018, 8(1): 4588.
74.	Oda H, Okuda Y, Yoshida Y, et al. Phenobarbital reduces blood glucose and Gluconeogenesis through down-regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression in rats. Biochem Biophys Res Commun, 2015, 466(3): 306-311.
75.	Fathallah N, Slim R, Larif S, et al. Drug-induced hyperglycaemia and diabetes. Drug Saf, 2015, 38(12): 1153-1168.
76.	Verrotti A, laTorre R, Trotta D, et al. Valproate-induced insulin resistance and obesity in children. Horm Res, 2009, 71(3): 125-131.
77.	王瑩, 宋凡. 非酮癥高血糖性癲癇發作 15 例臨床分析. 山東醫藥, 2012, 52(32): 48-50.
78.	Peng S, Yang J, Wang Y, et al. Low-dose intranasal insulin improves cognitive function and suppresses the development of epilepsy. Brain Res, 2020, 1726: 146474.
79.	O'Malley D, Shanley LJ, Harvey J. Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-Activated K+ channels. Neuropharmacology, 2003, 44(7): 855-863.
80.	DeBundel D, Fafouri A, Csaba Z, et al. Trans-modulation of the somatostatin type 2A receptor trafficking by insulin-regulated aminopeptidase decreases limbic seizures. JNeurosci, 2015, 35(34): 11960-11975.
81.	Wei X, Liu X, TanC, et al. Insulin attenuates epileptiform Discharge-induced oxidative stressby increasing zinc-α2-Glycoprotein in primary cultured cortical neurons. Neuro Report, 2019, 30(8): 580-585.
82.	Nandini HS, Yam NP, Krishna KL. Envision in the neuro protective effect of Metformin in experimental epilepsy: A portrait of molecul arcrosstalk. Life Sciences, 2019, 233: 116686.
83.	Okada K, Yamashita U, Tsuji S. Ameliorative effect of pioglitazone onseizure responses in genetically epilepsy-susceptible EL mice. BrainRes, 2006, 1102(1): 175-178.
84.	Wong SB, Cheng SJ, Hung WC, et al. Rosiglitazone suppresses in hippocampal slice by inhibiting presynaptic glutamate release in a medelof temporal lobe epilepsy. PLos One, 2015, 10(12): e0144806.
85.	Koshal P, Jamwal S, Kumar P. Glucagon-like Peptide-1(GLP-1) and neuro transmitters signaling in epilepsy: An insight review. Neuropharmacology, 2018, 136: 271-279.
86.	溫躍桃, 吳昆侖, 石全紅. 維格列汀通過上調胰高血糖素樣肽 1 發揮抗癲癇作用. 南方醫科大學學報, 2017, 37(1): 36-43.
87.	林鎮洲. 格列本脲在大鼠癲癇持續狀態腦水腫模型的神經保護作用及其機制研究. 廣州: 南方醫科大學, 博士學位論文, 2017.
88.	Singh P, Rao SC, Parikh R. Neonatal diabetes with intractable epilepsy: DEND syndrome. Indian J Pediatr, 2014, 81(12): 1387-1388.
89.	王利柱. 托吡酯聯合卡馬西平治療糖尿病合并癲癇患者的效果. 慢性病學雜志, 2020, 21(4): 558-560.
90.	曹建璽. 糖尿病合并癲癇持續狀態 90 例臨床觀察. 糖尿病新世界, 2014, (12): 41.

1. Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020, 369: m997.
2. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
3. Keezer MR, Novy J, Sander JW. Type 1 diabetes mellitus in people with Pharmacoresistant epilepsy: Prevalence and clinical characteristics. Epilepsy Res, 2015, 115: 55-57.
4. TiamkaoS, Pratipanawatr T, Tiamkao S, et al. Seizures in nonketotic hyperglycaemia perglycaemia. Seizure, 2003, 12(6): 409-410.
5. Schober E, Otto K P, Dost A, et al. Association of epilepsy and type 1 diabetes mellitus in children and adolescents: Is there an increased risk for diabetic ketoacidosis? J Pediatr, 2012, 160(4): 662-666.
6. Dafoulas GE, Toulis KA, Mccorry D, et al. Type 1 diabetes mellitus and risk of incidentpilepsy: apopulation-based, open-cohort study. Diabetologia, 2016, 60(2): 258-261.
7. Chou IC, Wang CH, Lin WD, et al. Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study. Diabetologia, 2016, 59(6): 1196-1203.
8. Mastrangelo M, Tromba V, Silvestri F, et al. Epilepsy in children withtype 1 diabetes mellitus: Pathophysiological basis and clinical hallmarks. Eur J Paediatr Neurol, 2019, 23(2): 240-247.
9. Yan D, Zhao E, Zhang H, et al. Associationbetween Type 1 diabetes mellitus and risk of epilepsy: A meta-analysis of observational studies. DrugDiscovTher, 2017, 11(3): 146-151.
10. Marcovecchio ML, Petrosino MI, Chiarelli F. Diabetes and epilepsy in children andadolescents. Curr Diab Rep, 2015, 15(4): 21.
11. Lu CL, Chang YH, Sun Y, et al. A population-based study of epilepsy incidence in association with type 2 diabetes and severe hypoglycaemia. Diabetes Research and Clinical Practice, 2018, 140: 97-106.
12. Mccorry D, Nicolson A, Smith D, et al. An association between type 1 diabetes and idiopathic generalized epilepsy. AnnNeurol, 2006, 59(1): 204-206.
13. Hamed SA. Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions. Epilepsy Res, 2007, 75(1): 1-9.
14. Doneray H, Houghton J, Tekgunduz KS, et al. Permanent neonatal diabetes mellitus caused by anovel mutation in the KCNJ11 gene. J Pediatr Endocrinol Metab, 2014, 27(3-4): 367-371.
15. Masia R, Koster JC, Tumini S, et al. An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal Diabetes. Diabetes, 2007, 56(2): 328-336.
16. Poulton C, Schot R, Kia S, et al. Microcephaly with Simplified Gyration, Epilepsy, and Infantile Diabetes Linked to Inappropriate Apoptosis of NeuralProgenitors. AmJHumGenet, 2011, 89(2): 265-276.
17. Verrotti A, Scaparrotta A, Olivieri C, et al. Seizures and type 1 diabetes mellitus: current state of knowledge. Eur J Endocrinol, 2012, 167(6): 749-758.
18. Antony S, Kumar TP, Kuruvilla KP, et al. Decreased GABA receptor binding in the cerebral cortex of insulin induced Hypogly cemic and Streptozocin induced diabetes rats. Neurochem Res, 2010, 35(10): 1516-21.
19. Szeto V, Chen NH, Sun HS, et al. The role of KATP channels in cerebra ischemic stroke and diabetes. ActaPharmacolSin, 2018, 39(5): 683-694.
20. Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med, 2011, 49(3): 435-41.
21. Gorgone G, Caccamo D, Pisani L R, et al. Hyperhomocysteinemia in patients with epilepsy: Does it play a role in the pathogenesis of brain atrophy? A preliminary report. Epilepsia, 2009, 50(1): 33-36.
22. Quan Y, Barszczyk A, Feng ZP, et al. Current understanding of KATP channels in neonatal diseases: focus on insulin secretion disorders. Acta Pharmacol Sin, 2011, 32(6): 765-780.
23. Velísek L, Velísková J, Chudomel O, et al. Metabolic environment in substantia nigra reticulata is critical for the expression and controlof hypoglycemia-induced seizure. J Neurosci, 2008, 28(38): 9349-9362.
24. Lv RJ, He JS, Fu Y H, et al. ASIC1a polymorphism is associated with temporal lobe epilepsy. Epilepsy Res, 2011, 96(1-2): 74-80.
25. 魏東. 酸敏感離子通道 1a 的通道開放、藥物調控及其在癲癇發生中的作用. 西安: 第四軍醫大學, 博士學位論文, 2015.
26. Wang YC, Li WZ, Wu Y, et al. Acid-sensing ion channel 1a contributes to the effect of extracellular acidosis on NLRP1 inflammasome activation in cortical neurons. J Neuroinflammation, 2015, 12: 246.
27. Ziemann AE, Schizler MK, Albert GW, et al. Seizure termination by acidosis depends on ASIC1a. Nat Neurosci, 2008, 11(7): 816-822.
28. Cho JH, Askwith CC. Presynaptic ralease probability is increased inHippocampal neurons from ASIC1 knockout mice. J Neurophysiol, 2008, 99(2): 426-41.
29. Ievglevsky O, Isae D, Netsy O, et al. Acid-sensing ion channels regulate spontaneous inhibitory activity in the hippocampus: possibleImplications for epilepsy. Philos Trans R Soc Lond B Biol Sci, 2016, 371(1700): 20150431.
30. 郭為. 酸敏感離子通道 1a 在大腦皮質發育不良病理發生中的作用研究. 重慶: 第三軍醫大學, 博士學位論文, 2014.
31. 陳勇, 葛金芳, 陳飛虎. 酸敏感離子通道 1a 在自身免疫性疾病發病機制中的研究進展. 中國藥理學通報, 2018, 34(1): 12-15.
32. 張海濤. 海馬區神經元葡萄糖低代謝在癲癇發生中的作用及機制研究. 西安: 第四軍醫大學, 博士學位論文, 2017.
33. Moloney TC, Idris I, Waters P, et al. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study. J Neurol Neurosurg Psychiatry, 2016, 87(6): 676-677.
34. Liimatainen S, Honnorat J, Pittock SJ, et al. GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies. Orphanet J Rare Dis, 2018, 13(1): 55.
35. kash SF, Johnson RS, Tecott LH, et al. Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Nat1 Acad Sci USA, 1997: 94.
36. Mahmoud AA, Abdelmagid T, Alghofely M, et al. Epilepsy in patients with insulin-dependent diabetes and relation to glutamic acid decarboxylase 65. Neurosciences, 2020, 25(3): 200-204.
37. Mitoma H, Song SY, Ishida K, et al. Presyhaptic impair ment of cerebellar inhibitory synapses by an auto antibody toglutamate decar boxylase. J Neurol Sci, 2000, 175: 40-44.
38. Tao H, Zhou X, Zhao B, et al. Conflicting effects of methylglyoxal and potential significance of miRNAs for seizure treatment. Front Mol Neurosci, 2018, 11: 70.
39. Byun K, Bayarsaikhan E, Kim D, et al. Activated microglial cells synthesize and secrete AGE-albumin. Ana Cell Biol, 2012, 45(1): 47-52.
40. Alyu F, Dikmen M. Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms. Acta Neuropsychiatr, 2017, 29(1): 1-16.
41. 劉卉, 姜振鋒, 姚麗芬. 晚期糖基化終末產物受體與癲癇炎癥機制相關性的研究. 腦與神經疾病雜志, 2019, 27(9): 592-595.
42. 陳勝利, 曹立榮, 紀盛章. 非酮癥性高血糖腦部影像學表現. 臨床放射學雜志, 2009, 28(2): 163-166.
43. Jin R, Jin ZG, Cai H. Influence of electroacupuncture plus jasminoidia intervention on expression of OX-42 and nuclear factor-kappa B in hippocampus and amygdale in cerebral ischemia plus diabetes rats. Acupuncture research, 2014, 39(4): 305-312.
44. Shlobin NA, Sander JW. Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review. Epilepsy Behav, 2020, 106: 107043.
45. Miklossy J, McGeer PL. Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. Aging (Albany NY), 2016, 8(4): 575-588.
46. Vezzani A, Fujinami RS, White HS, et al. Infections, inflammation and epilepsy. Acta Neuropathol, 2016, 131(2): 211-234.
47. 楊華俊, 郭安臣, 王群. 癲癇的發病機制研究進展. 科技導報, 2017, 35(4): 54-59.
48. Jordan AJ, Manor B, Novak V. Slow gaitspeed-an indicator of lowercere bralvaso reactivity in type 2 diabetes mellitus. Frontiersin Aging Neuroscience, 2014, 6: 135.
49. Poittevin M, Bonnin P, Pimpie C, et al. Diabetic microangiopathy: Impact of impaired cerebral vasoreactivity and delayed angiogenesisafter permanent middle cerebral artery occlusion on stroke damage andcerebral repair in mice. Diabetes, 2015, 64(3): 999-1010.
50. 殷盛明, 劉純青, 高溪, 等. 大鼠腦缺血對癲癇敏感性和腦內膠質原纖維酸性蛋白免疫反應的影響. 基礎醫學與臨床, 2003, (1): 53-58.
51. Xia L, Lei Z, Shi Z, et al. Enhanced autophagy signaling in diabeticrats with ischemia-induced seizures. Brain Res. 2016, 1643: 18-26.
52. PrasadS, SajjaRK, NaikP, et al. Diabetes mellitus and blood-brain Barrier dysfunction: an overview. J Pharmacovigil, 2014, 2(2): 125.
53. Vavilala MS, Richards TL, Roberts JS, et al. Change in blood-brain barrier permeability during pediatric diabetic ketoacidosis treatment. Pediatric Critical Care Medicine, 2010, 11(3): 332-338.
54. Fouyas IP, Kelly PA, Ritchie IM, et al. Cerebrovascular responses to pathophysiological insult in diabetic cats. J Clin Neurosci, 2003, 10: 88-91.
55. Dadas A, Janigro D. Breakdown of blood brain barrier asa mechanism of post-traumatic epilepsy. Neurobiol Dis, 2019, 23: 20.
56. Abdullahi W, Brzica H, Hirsch NA, et al. Functional expression of organic anion transporting polypeptide 1a4Is regulated by transforming growth factor-β/activin rector-like kinase 1 signaling at the blood-brain barrier. MolPharmacol, 2018, 94(6): 1321.
57. Hawkins RA, O'kane RL, Simpson IA, et al. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr, 2006, 136(1): 218-226.
58. 耿喜林, 徐明麗, 尹潔, 等. 糖尿病早期腦損傷與線粒體功能障礙. 中國病理生理雜志, 2012, 28(9): 1571-1576.
59. 姜東朗, 馮洪波, 邱湘哲, 等. ¹⁸F-FDGPET/CT 評價糖尿病前期患者腦葡萄糖代謝的改變. 中國醫學影像技術, 2016, 32(8): 1184-1188.
60. Zilberter Y, Zilberter M. The vicious circle of hypometabolism inNeurodegenerative diseases: Ways and mechanisms of matabolic correction. JNeurosciRes, 2017, 95(11): 2217-2235.
61. Shima T, Jesmin S, Matsui T, et al. Differential effects of type 2 diabetes on brain glycometabolism in rats: focus on glycogen and monacarboxylate transporter 2. J Physiol Sci, 2018, 68(1): 69-75.
62. DiNuzzo M, Mangia S, Maraviglia B, et al. Does abnormal glycogen structure contribute to increased susceptibility to seizures in epilepsy. Metab Brain Dis, 2015, 30(1): 307-316.
63. Tricò D, Herzog RI. Metabolic brain adaptations to recurrent hypoglycaemia may explain the link between type 1 diabetes mellitus andepilepsy and point towards future study and treatment options. Diabetologia, 2017, 60(5): 938-939.
64. 王慧萌, 趙志剛. 血糖水平對糖尿病缺血性腦損傷影響研究進展. 中華實用診斷與治療雜志, 2016, 30(2): 114-116.
65. 朱責梅, 楊絲絲, 伍迪, 等. 胰島素抵抗與糖尿病腦病. 生理科學進展, 2016, 47(5): 395-400.
66. 周佳秀, 田紹文, 曠昕. 能量代謝在癲癇疾病中的研究進展. 新醫學, 2019, 50(12): 881-885.
67. Stauss HM, Stangl H, Clark KC, et al. Cervical vagal nerve stimulation impairs glucose tolerance and suppresses insulin release in conscious rats. Physiol Rep, 2018, 6(24): e13953.
68. Meyers EE, Kronemberger A, Lira V, et al. Contrasting effects of afferent and efferent vagal nerve stimulation on insulin secretion and Blood glucose regulation. Physiol Rep, 2016, 4(4): e12718.
69. 江波, 鄒大進, 馬向華, 等. 生酮飲食干預2型糖尿病中國專家共識(2019年版). 實用臨床醫藥雜志, 2019, 23(3): 1-6.
70. Bolla AM, Caretto A, Laurenzi A, et al. Low-carb and ketogenic diets in type 1 and type 2 diabetes. Nutrients, 2019, 11(5): 962.
71. Genc BO, Dogan EA, Dogan U, et al. Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic Epilepsy receiving topiramate treatment. J Clin Neurosci, 2010, 17(10): 1256-1259.
72. Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: An update. Am Fam Physician, 2016, 94(3): 227-234.
73. Lee JTC, Shanina I, Chu YN, et al. Carbamazepine, a beta-cell protecting Drug, reduces type 1 diabetes incidence in NOD mice. Sci Rep, 2018, 8(1): 4588.
74. Oda H, Okuda Y, Yoshida Y, et al. Phenobarbital reduces blood glucose and Gluconeogenesis through down-regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression in rats. Biochem Biophys Res Commun, 2015, 466(3): 306-311.
75. Fathallah N, Slim R, Larif S, et al. Drug-induced hyperglycaemia and diabetes. Drug Saf, 2015, 38(12): 1153-1168.
76. Verrotti A, laTorre R, Trotta D, et al. Valproate-induced insulin resistance and obesity in children. Horm Res, 2009, 71(3): 125-131.
77. 王瑩, 宋凡. 非酮癥高血糖性癲癇發作 15 例臨床分析. 山東醫藥, 2012, 52(32): 48-50.
78. Peng S, Yang J, Wang Y, et al. Low-dose intranasal insulin improves cognitive function and suppresses the development of epilepsy. Brain Res, 2020, 1726: 146474.
79. O'Malley D, Shanley LJ, Harvey J. Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-Activated K+ channels. Neuropharmacology, 2003, 44(7): 855-863.
80. DeBundel D, Fafouri A, Csaba Z, et al. Trans-modulation of the somatostatin type 2A receptor trafficking by insulin-regulated aminopeptidase decreases limbic seizures. JNeurosci, 2015, 35(34): 11960-11975.
81. Wei X, Liu X, TanC, et al. Insulin attenuates epileptiform Discharge-induced oxidative stressby increasing zinc-α2-Glycoprotein in primary cultured cortical neurons. Neuro Report, 2019, 30(8): 580-585.
82. Nandini HS, Yam NP, Krishna KL. Envision in the neuro protective effect of Metformin in experimental epilepsy: A portrait of molecul arcrosstalk. Life Sciences, 2019, 233: 116686.
83. Okada K, Yamashita U, Tsuji S. Ameliorative effect of pioglitazone onseizure responses in genetically epilepsy-susceptible EL mice. BrainRes, 2006, 1102(1): 175-178.
84. Wong SB, Cheng SJ, Hung WC, et al. Rosiglitazone suppresses in hippocampal slice by inhibiting presynaptic glutamate release in a medelof temporal lobe epilepsy. PLos One, 2015, 10(12): e0144806.
85. Koshal P, Jamwal S, Kumar P. Glucagon-like Peptide-1(GLP-1) and neuro transmitters signaling in epilepsy: An insight review. Neuropharmacology, 2018, 136: 271-279.
86. 溫躍桃, 吳昆侖, 石全紅. 維格列汀通過上調胰高血糖素樣肽 1 發揮抗癲癇作用. 南方醫科大學學報, 2017, 37(1): 36-43.
87. 林鎮洲. 格列本脲在大鼠癲癇持續狀態腦水腫模型的神經保護作用及其機制研究. 廣州: 南方醫科大學, 博士學位論文, 2017.
88. Singh P, Rao SC, Parikh R. Neonatal diabetes with intractable epilepsy: DEND syndrome. Indian J Pediatr, 2014, 81(12): 1387-1388.
89. 王利柱. 托吡酯聯合卡馬西平治療糖尿病合并癲癇患者的效果. 慢性病學雜志, 2020, 21(4): 558-560.
90. 曹建璽. 糖尿病合并癲癇持續狀態 90 例臨床觀察. 糖尿病新世界, 2014, (12): 41.

Previous Article
肌陣攣與肌陣攣癲癇
Next Article
拉考沙胺和吡侖帕奈單藥治療癲癇的研究進展

Journal of Epilepsy

癲癇與糖尿病的相關性研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content